dc.contributor.author |
Ascher-Svanum, Haya |
dc.contributor.author |
Novick, Diego |
dc.contributor.author |
Haro Abad, Josep Maria |
dc.contributor.author |
Bertsch, Jordan |
dc.contributor.author |
McDonnell, David |
dc.contributor.author |
Detke, Holland |
dc.date |
2014 |
dc.identifier |
https://ddd.uab.cat/record/185065 |
dc.identifier |
urn:10.2147/NDT.S61409 |
dc.identifier |
urn:oai:ddd.uab.cat:185065 |
dc.identifier |
urn:pmid:25018631 |
dc.identifier |
urn:pmcid:PMC4074182 |
dc.identifier |
urn:pmc-uid:4074182 |
dc.identifier |
urn:articleid:11782021v10p1125 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/7880f945-6a16-42ee-9e73-9bbf7b69c00a |
dc.identifier |
urn:scopus_id:84903123643 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:4074182 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Neuropsychiatric Disease and Treatment ; Vol. 10 (june 2014), p. 1125-1131 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by-nc/4.0/ |
dc.subject |
Antipsychotics |
dc.subject |
Functioning |
dc.subject |
Olanzapine long-acting injection |
dc.subject |
Quality of life |
dc.subject |
Schizophrenia |
dc.title |
Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection |
dc.type |
Article |
dc.description.abstract |
Little is known about the long-term changes in the functioning of schizophrenia patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether observed changes differ from those seen with oral olanzapine. This study describes changes in the levels of functioning among outpatients with schizophrenia treated with olanzapine-LAI compared with oral olanzapine over 2 years. This was a secondary analysis of data from a multicenter, randomized, open-label, 2-year study comparing the long-term treatment effectiveness of monthly olanzapine-LAI (405 mg/4 weeks; n=264) with daily oral olanzapine (10 mg/day; n=260). Levels of functioning were assessed with the Heinrichs-Carpenter Quality of Life Scale. Functional status was also classified as "good", "moderate", or "poor", using a previous data-driven approach. Changes in functional levels were assessed with McNemar's test and comparisons between olanzapine-LAI and oral olanzapine employed the Student's t -test. Over the 2-year study, the patients treated with olanzapine-LAI improved their level of functioning (per Quality of Life total score) from 64.0-70.8 (P <0.001). Patients on oral olanzapine also increased their level of functioning from 62.1-70.1 (P <0.001). At baseline, 19.2% of the olanzapine-LAI-treated patients had a "good" level of functioning, which increased to 27.5% (P <0.05). The figures for oral olanzapine were 14.2% and 24.5%, respectively (P <0.001). Results did not significantly differ between olanzapine-LAI and oral olanzapine. In this 2-year, open-label, randomized study of olanzapine-LAI, outpatients with schizophrenia maintained or improved their favorable baseline level of functioning over time. Results did not significantly differ between olanzapine-LAI and oral olanzapine. |